Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-820-1 | CAS number: 127-06-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The two-generation reproductive toxicity study is waived in accordance with Annex IX, 8.7.3 column 1 of the REACH regulation. The available 90 day subchronic study indicates no adverse effects on reproductive organs or tissues.
Short description of key information:
The two generation reproductive toxicity study is waived as not scientifically justified.
Effects on developmental toxicity
Description of key information
The substance did not give rise to developmental toxicity in the rat.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted according to OECD guidelines under GLP conditions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Kingston, NY
- Age at study initiation: 90 days old
- Weight at study initiation: 222 - 291 g
- Housing: Individually in wire-mesh stainless steel cages
- Diet (e.g. ad libitum): Purina Certified Rodent Meal No. 5002
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 13 days prior to mating
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 17.7 - 26.1
- Humidity (%): 64-70
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Dosage solutions were administered orally by gavage as a single dose daily from gestation day 6 through gestation day 15. Individual doses were calculated using the most recent body weight data. Dose levels were 0 (distilled water control), 60, 200 or 600 mg MEKO/kg body weight. The dose volume was 10 mL/kg.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test substance, MEKO, was analyzed for purity and the test solutions were analyzed for homogeneity and stability by a gas chromatographic
procedure using a Poropack P column and a flame ionization detector. Overall the material used was > 99% pure and recoveries were ~ 99-100%.
Stability over the course of the dosing period was > 93%. - Details on mating procedure:
- Selected females were cohabitated with male rats of the same strain and source. Evidence of mating was determined by the presence of a copulatory plug in the vagina or a sperm positive vaginal smear. The day evidence of copulation was observed was designated day 0 of gestation and the female rats were assigned consecutively, in a block design, to study groups.
- Duration of treatment / exposure:
- Gestation Days 6-15.
- Frequency of treatment:
- Daily.
- Duration of test:
- Until sacrifice on Gestation Day 20.
- Remarks:
- Doses / Concentrations:
0, 60, 200 or 600 mg/kg bw/day
Basis:
actual ingested - No. of animals per sex per dose:
- 25 females/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels for this rat developmental toxicity studies were based on results of a range finding study in which groups of 6 pregnant rats received MEKO at levels of 25, 100, 200 or 400 mg/kg bw/day on gestation days 6-15. Hematological status was evaluated by measuring methemoglobin and reticulocyte levels. Mothers were sacrificed on gestation day 20 for Cesarean ection evaluations. Fetal evaluations in the range finding study were limited to external observations. All dams survived treatment. Clinical signs of toxicity were observed at 400 mg/kg bw/day including transient central nervous system depression. Dose-related increases in the levels of reticulocytes and methemoglobin occurred at all dose levels throughout gestation. Methemoglobin levels at 400 mg/kg bw/day were as high as 39%. Enlarged black/purple spleens were found at dose levels of 100 mg/kg bw/day and above. These effects suggested anemia was induced by the treatment. No adverse effects on gestational parameters such as the number of resorptions, viable fetuses and fetal weights were found. No fetal external malformations or developmental variations were observed. Statistical analyses were not performed in the range finding study.
- Maternal examinations:
- - During the experimental period, all animals were observed daily for clinical signs of toxicity including physical or behavioral abnormalities.
- Mortality checks were perfomed twice daily, in morning and afternoon.
- During the dosing period, the females were observed between one-half hour and two hours following dosing for overt signs of toxicity.
- Body weights of individual animals were measured and recorded on gestation days 0, 6, 9, 12, 16 and 20. Body weight changes were calculated for the following gestation intervals: 0.-6, 6-9, 9-12, 12-16, 16-20, 6-16 and 0-20.
- Food consumption was measured (as g/animal/day and g/kg/day) during gestation days 0-6, 6-9, 9-12, 12-16 and 16-20. - Ovaries and uterine content:
- After sacrifice on day 20, the uterus was removed from the body, examined externally, weighed, and then opened fo an internal examination. The number of viable and nonviable fetuses, early and late resorptions was recorded beginning with the left distal uterine horn, noting the position of the cervix, and continuing with the right uterine horn. Corpora lutea were counted and recorded for each ovary. Uteri with no macroscopic evidence of implants were placed in 10% aqueous ammonium sulfide for detection of early embryolethality.
- Fetal examinations:
- Fetuses were examined for external, visceral and skeletal abnormalities. Developmental malformations and variations were classfied based on the severity of the anatomical change(s) and their potential interference with organ and/or body functions.
- Statistics:
- Statistical analyses were performed by a Digital Vax 11/730 computer. All analyses were two-tailed with a minimal significance level of 5%. One-way analysis of variance followed by Dunnett's test was used to analyze maternal and fetal data including body weights, food consumption, number of viable fetuses, implantation sites, and corpora lutea. The Mann-Whitney U test was used to compare post-implantation loss, dead fetuses, and resorptions. Fetal sex ratios were analyzed using the Chi-Square test. Fisher's Exact test was used to analyze the incidence and number of fetal malformations. and variations utilizing the dam (litter) as the experimental unit.
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Clinical signs of toxicity were observed at 200 and 600 mg/kg bw/day. These clinical signs (signs of general nervous system depression) were generally transient and had disappeared before dosing on the following day. Also, body weight losses and/or reduced body weight gain and reduced food consumption was seen in these dose groups. No treatment-related clinical signs were observed at the 60 mg/kg/day treatment level. Enlarged spleens were seen at necropsy in all MEKO-treated animals but not in the controls. Thus, the NOEL for the maternal animals was not established. - Dose descriptor:
- NOAEL
- Effect level:
- 600 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- Maternal oral exposure to methyl ethyl ketoxime (MEKO) at concentrations up to 600 mg/kg bw/day during gestation days 6 through 15 did not induce developmental toxicity in rats. In this study, the NOEL for developmental toxicity in the rat was 600 mg/kg bw/day. Maternal toxicity was noted in all MEKO treated rats (60, 120 and 600 mg/kg bw/day).
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 600 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Sufficient to meet data requirements. The study is Klimisch 2.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The developmental toxicity assessment of acetone oxime is based on read-across data from the structurally related substance butanone oxime (Methyl ethyl ketoxime, MEKO, CAS 96-29-7).
Maternal oral exposure to methyl ethyl ketoxime (MEKO) at concentrations up to 600 mg/kg bw/day during gestation days 6 through 15 did not induce developmental toxicity in rats. In this study, the NOEL for developmental toxicity in the rat was 600 mg/kg bw/day. Maternal toxicity was noted in all MEKO treated rats (60, 120 and 600 mg/kg bw/day).
Justification for selection of Effect on developmental toxicity: via oral route:
Only one study available.
Justification for classification or non-classification
There is no evidence from the available studies to indicate that the substance is toxic to reproduction and it is therefore not classified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.